DYN

SEC source: 0001209191-22-053212 · doc4.xml · derivative · entry 7

Brumm Joshua T · CIK 0001528826 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 543,549

Underlying: Common Stock · 14,200 shares

Expires 2030-01-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on October 12, 2020 and the remaining shares vesting in equal quarterly installments thereafter.

SEC source: 0001209191-22-053212 · doc4.xml · nonDerivative · entry 2

Brumm Joshua T · CIK 0001528826 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 204,623

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $12.70 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) of this Form 4.

SEC source: 0001209191-22-053212 · doc4.xml · nonDerivative · entry 1

Brumm Joshua T · CIK 0001528826 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 218,823

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-22-050881 · doc4.xml · nonDerivative · entry 1

Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,825

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 20, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $13.70 to $13.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.

F3 · balance_after: Includes 39,323 unvested RSUs.

SEC source: 0001209191-22-050893 · doc4.xml · nonDerivative · entry 1

Scalzo Richard William · CIK 0001789545 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,495

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 20, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $13.70 to $13.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.

F3 · balance_after: Includes 19,300 unvested RSUs.

SEC source: 0001209191-22-050891 · doc4.xml · nonDerivative · entry 1

McNeill Jonathan · CIK 0001824673 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,222

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 20, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $13.70 to $13.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.

F3 · balance_after: Includes 29,072 unvested RSUs.

SEC source: 0001209191-22-050884 · doc4.xml · nonDerivative · entry 1

Brumm Joshua T · CIK 0001528826 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 204,623

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 20, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $13.70 to $13.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.

F3 · balance_after: Includes 149,544 unvested RSUs.

SEC source: 0001209191-22-050888 · doc4.xml · nonDerivative · entry 1

HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,786

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 20, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $13.70 to $13.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.

F3 · balance_after: Includes 50,710 unvested RSUs.

SEC source: 0001209191-22-050117 · doc4.xml · nonDerivative · entry 1

Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,238

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 15, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $14.05 to $14.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.

F3 · balance_after: Includes 44,145 unvested RSUs.

SEC source: 0001209191-22-050127 · doc4.xml · nonDerivative · entry 1

Scalzo Richard William · CIK 0001789545 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,335

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 15, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $14.05 to $14.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.

F3 · balance_after: Includes 22,166 unvested RSUs.

SEC source: 0001209191-22-050123 · doc4.xml · nonDerivative · entry 1

Farwell Wildon · CIK 0001847941 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,724

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 15, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $14.05 to $14.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.

F3 · balance_after: Includes 55,625 unvested RSUs.

SEC source: 0001209191-22-050122 · doc4.xml · nonDerivative · entry 1

McNeill Jonathan · CIK 0001824673 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,468

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 15, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $14.05 to $14.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.

F3 · balance_after: Includes 33,325 unvested RSUs.

SEC source: 0001209191-22-050120 · doc4.xml · nonDerivative · entry 1

HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,415

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 15, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $14.05 to $14.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.

F3 · balance_after: Includes 59,686 unvested RSUs.

SEC source: 0001209191-22-050119 · doc4.xml · nonDerivative · entry 1

Brumm Joshua T · CIK 0001528826 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 216,459

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 15, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $14.05 to $14.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.

F3 · balance_after: Includes 176,301 unvested RSUs.

SEC source: 0001209191-22-042058 · doc4.xml · derivative · entry 1

Scalzo Richard William · CIK 0001789545 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2032-07-10

F1 · derivative.exercise_date: This option was granted on July 11, 2022. The shares underlying the option are scheduled to vest over four years in equal monthly installments from July 1, 2022.

SEC source: 0001209191-22-041330 · doc4.xml · nonDerivative · entry 2

Brumm Joshua T · CIK 0001528826 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 219,939

F3 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of PRSUs granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $8.24 to $8.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.

F2 · balance_after: Includes 183,688 unvested RSUs.

SEC source: 0001209191-22-041328 · doc4.xml · derivative · entry 1

Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,477

Underlying: Common Stock · 23,477 shares

Expires 2030-07-30

F1 · derivative.exercise_date: The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.

SEC source: 0001209191-22-041342 · doc4.xml · derivative · entry 1

Scalzo Richard William · CIK 0001789545 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,333

Underlying: Common Stock · 17,333 shares

Expires 2030-07-30

F1 · derivative.exercise_date: The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.

SEC source: 0001209191-22-041343 · doc4.xml · derivative · entry 1

Stehman-Breen Catherine · CIK 0001702233 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,222

Underlying: Common Stock · 7,222 shares

Expires 2030-07-30

F1 · derivative.exercise_date: The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.

SEC source: 0001209191-22-041339 · doc4.xml · derivative · entry 1

McNeill Jonathan · CIK 0001824673 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,666

Underlying: Common Stock · 21,666 shares

Expires 2030-07-30

F1 · derivative.exercise_date: The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.

SEC source: 0001209191-22-041335 · doc4.xml · derivative · entry 1

Klein Lawrence Otto · CIK 0001762583 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,222

Underlying: Common Stock · 7,222 shares

Expires 2030-07-30

F1 · derivative.exercise_date: The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.

SEC source: 0001209191-22-041337 · doc4.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,222

Underlying: Common Stock · 7,222 shares

Expires 2030-07-30

F1 · derivative.exercise_date: The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.

SEC source: 0001209191-22-041333 · doc4.xml · derivative · entry 1

HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,219

Underlying: Common Stock · 36,219 shares

Expires 2030-07-30

F1 · derivative.exercise_date: The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.

SEC source: 0001209191-22-041330 · doc4.xml · derivative · entry 4

Brumm Joshua T · CIK 0001528826 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,386

Underlying: Common Stock · 78,386 shares

Expires 2030-09-15

F6 · derivative.exercise_date: The option was granted on September 16, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.

SEC source: 0001209191-22-041330 · doc4.xml · derivative · entry 3

Brumm Joshua T · CIK 0001528826 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 153,931

Underlying: Common Stock · 153,931 shares

Expires 2030-07-30

F5 · derivative.exercise_date: The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.

SEC source: 0001209191-22-041330 · doc4.xml · nonDerivative · entry 1

Brumm Joshua T · CIK 0001528826 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 230,902

F1 · shares: The Performance Restricted Stock Units (PRSUs) were granted on September 17, 2020, with 100% of the PRSUs to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.

F2 · balance_after: Includes 183,688 unvested RSUs.

SEC source: 0001209191-22-037142 · doc4.xml · nonDerivative · entry 1

Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,950

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · balance_after: Includes 46,427 unvested RSUs.

SEC source: 0001209191-22-037153 · doc4.xml · nonDerivative · entry 1

Scalzo Richard William · CIK 0001789545 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,661

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · balance_after: Includes 23,209 unvested RSUs.

SEC source: 0001209191-22-037150 · doc4.xml · nonDerivative · entry 1

McNeill Jonathan · CIK 0001824673 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,962

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · balance_after: Includes 34,907 unvested RSUs.

SEC source: 0001209191-22-037143 · doc4.xml · nonDerivative · entry 1

Brumm Joshua T · CIK 0001528826 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 206,784

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · balance_after: Includes 183,688 unvested RSUs.

SEC source: 0001209191-22-037146 · doc4.xml · nonDerivative · entry 1

HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,201

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · balance_after: Includes 62,205 unvested RSUs.

SEC source: 0001209191-22-037145 · doc4.xml · nonDerivative · entry 1

Farwell Wildon · CIK 0001847941 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,382

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · balance_after: Includes 57,019 unvested RSUs.

SEC source: 0001209191-22-034493 · doc4.xml · derivative · entry 1

Klein Lawrence Otto · CIK 0001762583 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,596

Underlying: Common Stock · 19,596 shares

Expires 2032-06-02

F1 · derivative.exercise_date: This option was granted on June 3, 2022. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders.

SEC source: 0001209191-22-034681 · doc4.xml · derivative · entry 1

Rhodes Jason P · CIK 0001577014 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,596

Underlying: Common Stock · 19,596 shares

Expires 2032-06-02

F1 · derivative.exercise_date: This option was granted on June 3, 2022. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders.

F2 · ownership.direct: The Reporting Person is a member of Atlas Venture Associates XI, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-22-034499 · doc4.xml · derivative · entry 1

Stehman-Breen Catherine · CIK 0001702233 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,596

Underlying: Common Stock · 19,596 shares

Expires 2032-06-02

F1 · derivative.exercise_date: This option was granted on June 3, 2022. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders.

SEC source: 0001209191-22-034495 · doc4.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,596

Underlying: Common Stock · 19,596 shares

Expires 2032-06-02

F1 · derivative.exercise_date: This option was granted on June 3, 2022. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders.

SEC source: 0001209191-22-034491 · doc4.xml · derivative · entry 1

Kersten Dirk · CIK 0001823682 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,596

Underlying: Common Stock · 19,596 shares

Expires 2032-06-02

F1 · derivative.exercise_date: This option was granted on June 3, 2022. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders.

SEC source: 0001209191-22-034490 · doc4.xml · derivative · entry 1

HURWITZ EDWARD · CIK 0001211840 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,596

Underlying: Common Stock · 19,596 shares

Expires 2032-06-02

F1 · derivative.exercise_date: This option was granted on June 3, 2022. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders.

SEC source: 0001209191-22-018530 · doc4.xml · nonDerivative · entry 1

Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,676

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on March 11, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $8.65 to $8.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.

F3 · balance_after: Includes 48,709 unvested RSUs.

SEC source: 0001209191-22-018536 · doc4.xml · nonDerivative · entry 1

McNeill Jonathan · CIK 0001824673 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,466

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on March 11, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $8.65 to $8.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.

F3 · balance_after: Includes 36,489 unvested RSUs.

SEC source: 0001209191-22-018535 · doc4.xml · nonDerivative · entry 1

HIGH SUSANNA GATTI · CIK 0001691005 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,003

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on March 11, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $8.68 to $8.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.

F3 · balance_after: Includes 64,724 unvested RSUs.

SEC source: 0001209191-22-018537 · doc4.xml · nonDerivative · entry 1

Scalzo Richard William · CIK 0001789545 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,994

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on March 11, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $8.65 to $8.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.

F3 · balance_after: Includes 24,252 unvested RSUs.

SEC source: 0001209191-22-018533 · doc4.xml · nonDerivative · entry 1

Farwell Wildon · CIK 0001847941 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,050

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on March 11, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $8.65 to $8.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.

F3 · balance_after: Includes 58,413 unvested RSUs.

SEC source: 0001209191-22-018532 · doc4.xml · nonDerivative · entry 1

Brumm Joshua T · CIK 0001528826 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 210,324

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on March 11, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $8.67 to $8.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.

F3 · balance_after: Includes 191,074 unvested RSUs.

SEC source: 0001209191-22-015901 · doc4.xml · nonDerivative · entry 1

Farwell Wildon · CIK 0001847941 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,690

F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on March 2, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on March 2, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $8.56 to $8.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.

F3 · balance_after: Includes 59,807 unvested RSUs.

SEC source: 0001209191-22-016460 · doc4.xml · derivative · entry 1

Incerti Carlo · CIK 0001915358 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,193

Underlying: Common Stock · 39,193 shares

Expires 2032-03-01

F1 · derivative.exercise_date: The option was granted on March 2, 2022. The shares underlying the option are scheduled to vest over three years in equal monthly installments through March 2, 2025.

SEC source: 0001209191-21-069422 · doc4.xml · derivative · entry 2

Farwell Wildon · CIK 0001847941 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,935

Underlying: Common Stock · 67,935 shares

Expires 2031-12-09

F3 · derivative.exercise_date: This option was granted on December 10, 2021. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2025.

SEC source: 0001209191-21-069422 · doc4.xml · nonDerivative · entry 1

Farwell Wildon · CIK 0001847941 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,307

F1 · shares: Consists of shares of Common Stock issuable under 22,307 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2022.

F2 · balance_after: Includes 72,307 unvested RSUs. Each unvested RSU represents the right to receive one share of Common Stock upon vesting.

SEC source: 0001209191-21-069418 · doc4.xml · derivative · entry 2

Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,786

Underlying: Common Stock · 54,786 shares

Expires 2031-12-09

F3 · derivative.exercise_date: This option was granted on December 10, 2021. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2025.

SEC source: 0001209191-21-069418 · doc4.xml · nonDerivative · entry 1

Beskrovnaya Oxana · CIK 0001824542 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,369

F1 · shares: Consists of shares of Common Stock issuable under 36,524 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2022.

F2 · balance_after: Includes 50,991 unvested RSUs. Each unvested RSU represents the right to receive one share of Common Stock upon vesting.